<p>In this episode of the Illusion of Consensus podcast, Dr. Matt Johnson and I discuss the recent FDA decision regarding MDMA therapy for PTSD. The conversation covers the FDA's commitment to transparency in drug approval processes, the specific concerns raised in the rejection of MDMA therapy, and the implications for future psychedelic treatments. Dr. Johnson emphasizes the need for a fair evaluation process and the potential benefits of MDMA therapy compared to traditional SSRIs, while also addressing the importance of understanding the durability of treatment effects and the biases present in clinical trials.</p><p><strong>Chapters</strong></p><p><strong>00:00</strong>Introduction to Psychedelic Research and FDA Transparency</p><p><strong>02:39</strong>FDA's Rejection of MDMA Therapy: Key Concerns</p><p><strong>04:55</strong>Exploring the FDA's Feedback on MDMA Therapy</p><p><strong>12:18</strong>Durability of MDMA's Effects in PTSD Treatment</p><p><strong>16:59</strong>Comparing MDMA Therapy to SSRIs for PTSD</p><p><strong>20:51</strong>Effect Sizes and Future of Psychedelic Treatments</p><p><strong>28:38</strong>MDMA Use and Treatment Efficacy</p><p><strong>32:02</strong>Pre-Screening and Selection Bias in Trials</p><p><strong>34:38</strong>Durability of Treatment Effects</p><p><strong>36:32</strong>Long-Term Efficacy and Safety of SSRIs</p><p><strong>39:29</strong>Societal Factors in Mental Health Treatment</p><p><strong>42:43</strong>The Role of Psychedelics in Therapy</p><p><strong>46:50</strong>Future of Psychedelic Therapy and FDA Regulations</p> <br/><br/>This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit <a href="https://www.illusionconsensus.com/subscribe?utm_medium=podcast&#38;utm_campaign=CTA_2">www.illusionconsensus.com/subscribe</a>